Ad Zone

Share |

Tuesday, September 28, 2010

PhD in IISER, Trivanathapuram

Ph. D. Admissions, January 2011

Applications are invited from highly motivated students for admission to the Ph.D. programme beginning in January 2011 at the Indian Institute of Science Education and Research – Thiruvananthapuram.

Eligibility criteria

Biological Sciences

Masters degree in Biological/Chemical/Physical Sciences or MBBS. 60% marks or equivalent is desirable. Qualifying in one of the following national level tests with validity as on 1st of January 2011: CSIR-UGC-JRF/DBT-JRF/GATE/ICMR JRF. The second requirement (qualifying in a national test) is waived for applicants interested in pursuing a Ph.D. in ecological sciences. They will however be required to appear for a written screening test at IISER -TVM and only those shortlisted based on the screening will be allowed to appear for the interview.

Research Areas:

Microbial Cell Biology, Structural Biology, Cancer Biology, Ecology and Evolution, and Plant Biology

Chemical Sciences

Masters degree in Chemistry. 60% marks or equivalent is desirable. Qualifying in one of the following national level tests with validity as on 1st of January 2011: CSIR-UGC-JRF/GATE.

Physical Sciences

Masters degree in Physical Sciences, Engineering or Technology in areas closely related to the interests of the physics faculty at IISER TVM. 60% marks or equivalent is desirable. Qualifying in one of the following national level tests with validity as on 1st of January 2011: JEST/GATE/CSIRUGC-JRF. Applicants with M. Tech need a GATE score valid as of 1st January 2010

Mathematical Sciences

  1. Master's degree in Mathematics / Statistics / in a relevant area of science with desired CPI of 6.5 (or 60% of marks) and a valid CSIR UGC-JRF/NBHM/GATE/INSPIRE (PhD) as on 1st January 2011.
  2. Master's degree in Engineering / Technology in a relevant area with desired CPI of 6.5 (or 60% of marks) with valid GATE score as on 1st January 2010.
  3. Bachelor's degree in Engineering / Technology in a relevant area with a desired CPI of 7.0 (or 65% of marks), an appearance in the Indian National Math Olympiad (INMO) in class XI or XII, and a valid CSIRUGC-JRF/NBHM/GATE/INSPIRE (PhD) as on 1st January 2011.
  4. Eligibility criterion will be relaxed by CPI of 0.5 (or 5% of marks) for SC/ST candidates.

Research Areas:

Functional Analysis, Numerical Functional Analysis, Harmonic Analysis, Stochastic Process, Stochastic Partial Differential Equations, Mathematical Finance, Financial Engineering, Fluid Dynamics.

--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Surgery Can Lead to Long-Term Reduction in Stroke Risk

Successful surgery for narrowed arteries in the neck halves the risk of having a stroke over the next 5 years, and benefit persists for at least 10 years, an Oxford-led study has shown.

However, operating on the main arteries that take blood to the brain involves about a 3% risk of causing an immediate stroke.

Otherwise healthy patients who are discovered to have substantial narrowing of either of the main arteries in the neck are at an increased risk of having a stroke in the future. An operation, called a carotid endarterectomy (CEA), can remove the fatty deposits narrowing the artery, but the procedure itself causes some immediate risk of stroke or death.

In this long-running randomised trial, the researchers assessed whether the benefits of successful CEA procedures in reducing the likelihood of a stroke over the next 5 or 10 years balanced out the immediate risks of surgery in these patients.

The researchers conclude that there is likely to be net benefit from operating on those in good health under 75 years old, as long as the surgical risks remain low. Among older patients the immediate risk of surgery may outweigh the long-term benefit, however.

The study, published in the medical journal The Lancet and involving researchers from 30 countries, was led by Professor Alison Halliday of the Nuffield Department of Surgical Sciences and Professor Sir Richard Peto of the Clinical Trial Service Unit at the University of Oxford.

The study involved 3120 patients with narrowed carotid arteries in the neck where there was uncertainty about whether or not to have the surgery. Half were randomly allocated to have the operation immediately, and half to have indefinite deferral of the procedure until there was a definite need for it.

Among those who had surgery, the risk of stroke or death during or soon after the procedure was 3%.

But those who had surgery had a substantial reduction in their subsequent risk of a stroke. After 5 years, the stroke risk among those who had surgery immediately was 4.1% versus 10% for those who didn't. At 10 years, the risk was 10•8% among those who had the surgery against 16•9% in those who did not.

Professor Halliday said: 'This trial took more than 15 years to complete because we wanted to know about the long-term effects of surgery.

'The definite benefits that we have found will be of practical value to doctors and patients deciding in the future whether to take the immediate risk of having such surgery.'

The study was funded by the Medical Research Council, the BUPA Foundation and the Stroke Association.

Story Source: The above story is reprinted from materials provided by University of Oxford.

--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Sunday, September 19, 2010

The IBRO Asian-Pacific Regional Committee (APRC) announces IBRO School to be held @ National Brain Research Centre

The IBRO Asian-Pacific Regional Committee (APRC) announces an IBRO School to be held at the National Brain Research Centre, in Manesar, India, from November 29 - December 10, 2010, covering the theme: "Study of Human Brain Structure and Function using Magnetic Resonance Imaging and Spectroscopy." Application deadline : September 15, 2010.

Activities ;
The workshop will be held for two weeks from 29 Nov -10 Dec. 2010. The various components of the workshop will include :

Lectures
Lab practicals and training session
Interactive discussion groups
Social activities.
(1) Lectures: Lectures will be focused on analysis of data All lectures will be complemented by three sessions each day, namely Demonstration session, Practicals/Lab session, and Interactive Discussion/Training session the students will be divided into batches and asked to design and conduct a small research project.
In addition, the class will be divided into three groups ~10-12 students/group).

All lectures will be 50 minutes duration with a 20 minute coffee-break in between, , The faculty will use visual aids (e.g. powerpoint slides) where appropriate and provide outlines of each lecture and background reading lists to the students in advance of the workshop.

(2) Lab Practicals: Lab practicals/lab sessions will be designed to provide hands-on instruction in selected state-of-the-art techniques and will include structural and functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS), and electroencephalography (EEG).

(3) Interactive Session: Problem Solving/Tutorial Paper reading and discussion groups: During Interactive sessions the students will have intensive discussion with the faculty and tutors on the techniques being taught, and this will impart an opportunity to the students to hone their practice on the imaging techniques and. twill allow students to focus more deeply on topics of special interest and help them understand the basic perspective as well as state-of-the-art procedures.

(4) Social Activities: The workshop will be designed to facilitate informal interactions between participants (students, visiting faculty and resident faculty). Daily breakfast, lunch and morning/afternoon coffee breaks will provide for interactions between visiting faculty, resident faculty, and students with opportunities for discussions of science, as well as eastern vs. western views on life, culture, art and politics.In addition, the workshop will open with a reception, and conclude with a validectory session for all workshop participants. A tour of Delhi and nearby areas will be arranged over the weekend for the students.

Who Can Apply :
Graduate students, post doctoral fellows. Preferably those registered in a Ph.D program in the basic sciences or Medicine/ Engineering /Pharmacy /Veterinary sciences or any of the allied sciences.


Venue
National Brain Research Centre
National Highway - 8, Manesar
Gurgaon - 122 050
Haryana, INDIA
http://www.nbrc.ac.in

Location : National Brain Reseach Center is nearly 40 KM from Delhi International Airport and is connected to delhi by expressway(NH-8).

Contact Details :
Programme Coordinator - IBRO Workshop
National Brain Research Centre
National Highway - 8, Manesar
Gurgaon - 122 050
Haryana, INDIA
http://www.nbrc.ac.in
Email : conference@nbrc.ac.in

--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

How a Normally Defensive Immune Response Can Help HIV

Researchers have identified how a normal response to infection, one that usually serves to limit the amount of inflammation, actually contributes to disease progression and viral persistence in HIV-infected patients.

The findings, published in the May 19 issue of the journal Science Translational Medicine, offer important opportunities for further research, both for treatment of long-term persistence of HIV in those who are infected and for prevention of infection in those who are not, according to the study team.

The study, led by UCSF researchers, focused on the body's production of an enzyme called indoleamine 2,3-dioxygenase 1 (IDO1). To prevent the harm associated with chronic inflammation, the body typically turns on IDO1, which then serves to suppress inflammation and immune responses. In the setting of HIV infection, the authors found that IDO1 can instead alter the balance between two types of T-cells that have opposing functions.

One type of immune cell, called Th17, releases interleukin-17, a cytokine that has a central role in maintaining the integrity of the mucosal barrier in the gut. The other type, named Treg, prevents inflammation in a non-specific manner and can also turn off immune responses against viruses such as HIV.

The authors found that induction of IDO1 by HIV results in loss of Th17 cells and a relative increase in Tregs. This change in the balance of Th17 cells and Tregs allows bacteria to cross the mucosal barrier of the gut, initiating new inflammatory reactions in the process. At the same time, the increased number of Tregs may prevent the immune system from attacking HIV in areas of the body where strong HIV-specific immune responses are most needed. The altered Th17/Treg balance, in sum, leads to an endless cycle of inflammation induced by the invading microbes, more induction of IDO1, and continued loss of Th17 cells.

 

"In most instances, reducing inflammation following immune system activation to fight infection is beneficial. But, in HIV disease, this can establish a reinforcing cycle that is strongly linked to disease progression and that may help HIV to persist in patients, said study lead co-author, Jeff Mold, PhD, from the UCSF Division of Experimental Medicine. "Mucosal defenses are breached, microbes cross over, and inflammation results. This leads to increasing IDO1 activity, continued changes in the balance of Th17 and Treg cells, further weakening of the mucosal defenses, and even more inflammation."

The findings represent the next step in a series of research studies reported previously by the same group of investigators, showing that SIV infection of monkeys leading to AIDS is associated with a similar change in Th17 and Treg balances. The change in T cell balance was not observed in another primate, African green monkeys, where infection with SIV is harmless and does not cause disease.

In the current study, the investigators looked at IDO1 activity in HIV-infected human subjects at various stages of disease and in healthy non-infected subjects.

"We confirmed that IDO1 activity is associated with HIV disease progression. But we went further and also looked at the Th17 and Treg balance, and found that the change in the ratio leading to decreasing Th17 cells is also associated with HIV disease progression," said study lead co-author, David Favre, PhD, formerly at UCSF, now with the National Immune Monitoring Laboratory, Montreal.

With pharmacological inhibitors of IDO1 in development and currently in clinical trials for cancer immunotherapy, the finding may lead to new therapeutic approaches for assisting in the control of HIV disease, noted the study team.

"Most of an infected person's own immune responses that are known to affect HIV disease outcomes cannot be manipulated or altered clinically and, hence, have not really had much of an impact for patients. This work, however, is very different, as it has uncovered several possible pathways that might be addressed clinically with developing or available therapeutics," said study co-author, Steven Deeks, MD, professor of medicine at the UCSF Division of HIV/AIDS at San Francisco General Hospital.

IDO1 may play a role in the ability of HIV to persist in HIV-infected patients for their lifetimes, notwithstanding effective treatment with antiretroviral therapies.

"Steve Deeks and I are continuing to examine the role of IDO1 through a study recently announced by amfAR, the Foundation for AIDS Research, into whether the disruption of IDO1 will reduce the level of immune activation, which could then lead to a decrease in viral persistence," said senior study author Joseph M. McCune, MD, PhD, chief of the UCSF Division of Experimental Medicine.

In addition to Favre, Mold, Deeks, and McCune, other study co-authors include Peter Hunt, Bittoo Kanwar, Lillian Seu, Jason Barbour, Margaret Lowe, Anura Jayawardene, Francesca Aweeka, Yong Huang, Jeffrey Martin, and Frederick Hecht from UCSF; Daniel Douek and Jason Brenchley from the National Institute of Allergy and Infectious Diseases, NIH, and P'ng Loke from NYU.

The research was funded by grants from the Elizabeth Glaser Pediatric AIDS Foundation, the National Institute of Allergy and Infectious Diseases, the National Institutes for Health, the Harvey V. Berneking Living Trust, the UCSF-GIVI Center for AIDS Research, and the UCSF Clinical and Translational Institute Clinical Research Center.

--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

New Treatment for Rabies Advances After Successful Phase 1 Trial in India

With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

Details of the study were reported on September 14 at the American Society for Microbiology's 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston, Massachusetts in a poster presentation titled, "A Human Monoclonal Antibody to Rabies Virus Provides Protective Neutralizing Activity: Results of a Phase 1 Study," by researchers from MassBiologics; the Serum Institute of India in Pune, India; and King Edward Memorial Hospital (KEM) in Mumbai, India.

"We are very encouraged by the results from this trial," said Donna Ambrosino, MD, executive director of MassBiologics and a professor of pediatrics at the Medical School.

Subhash Kapre, PhD, of the Serum Institute of India, agreed saying, "The next step for clinical studies is already in the planning, and we are hopeful that this new therapy will have a major impact on rabies across the globe in the not too distant future."

The World Health Organization estimates that more than 10 million people are exposed to rabid animals each year, resulting in more than 55,000 deaths. Approximately 95 percent of human deaths from rabies occur in Asia and Africa. Untreated, the rabies virus causes an acute encephalitis that is fatal once symptoms appear; however the infection is preventable by prompt treatment following exposure, a procedure known as post-exposure prophylaxis (PEP) that involves administration of a rabies vaccine and rabies immune globulin (RIG) soon after exposure.

While the vaccine is often available, the preferred human rabies immune globulin (HRIG), which is derived from human blood, is expensive material and typically not available in developing countries. As an alternative to HRIG, equine immune globulin derived from horse serum is used in many parts of the world, but it is also scarce, expensive and can carry significant side effects. Too frequently, however, there is neither HRIG nor equine product available to treat all those in the developing world who are bitten by rabid animals.

To address the supply problems and side-effect issues, MassBiologics and the Serum of Institute of India launched an effort to develop a monoclonal antibody (MAB) that could be used in place of HRIG. Pre-clinical testing of RAB-1 showed that it neutralized all isolates available from a panel of rabies viruses. MassBiologics then partnered with the Serum Institute of India, which is one of the world's largest manufacturers of vaccines, including a major supplier of the rabies vaccine, to develop the capacity to produce monoclonal antibodies in India, and advance RAB-1 into clinical trials.

In the Phase 1 trial run at the KEM hospital, 74 healthy volunteers were randomized into several groups that either received escalating doses of RAB-1 or of HRIG combined with vaccine. The RAB-1 was well tolerated by all subjects, with no serious adverse side-effects caused by the MAB. Blood samples were then analyzed and showed the volunteers who received RAB-1 and vaccine at a dose of 0.150 mg/kg had levels of rabies antibodies equal to or higher than the levels from those volunteers who had received the standard does of HRIG and vaccine. The half life of RAB-1 was 18-19 days.

Blood samples were also analyzed by the Kansas State Veterinary Diagnostic Laboratory to determine if antibodies present in the volunteers' bloodstream could neutralize rabies virus in a cell-based assay using two different strains of virus. That data showed that volunteers who received RAB-1 at 0.150 mg/kg with vaccine had similar or better protective serum levels when compared to those who received HRIG with vaccine.

Following the successful conclusion of this Phase 1 trial, the Serum Institute of India and MassBiologics are moving ahead in a clinical trial in India to evaluate the efficacy of RAB-1 combined with vaccine compared to the standard of care for patients who have been exposed to potentially rabid animals. "Monoclonal antibodies can be produced in large quantities and at much lower costs than blood products, which could make this new therapy broadly available in Asia and India," Dr. Kapre said. "We remain optimistic that this program will eventually prevent thousands of deaths from rabies each year."



--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Universal Flu Vaccine Moving Closer

A universal influenza vaccine -- so-called because it could potentially provide protection from all flu strains for decades -- may become a reality because of research led by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

In experiments with mice, ferrets and monkeys, the investigators used a two-step immunization approach to elicit infection-fighting antibodies that attacked a diverse array of influenza virus strains. Current flu vaccines do not generate such broadly neutralizing antibodies, so they must be re-formulated annually to match the predominant virus strains circulating each year.

The research, led by NIAID scientist Gary J. Nabel, M.D., Ph.D., appears online ahead of print July 15 issue ofScience Express.

"Generating broadly neutralizing antibodies to multiple strains of influenza in animals through vaccination is an important milestone in the quest for a universal influenza vaccine," says NIAID Director Anthony S. Fauci, M.D. "This significant advance lays the groundwork for the development of a vaccine to provide long-lasting protection against any strain of influenza. A durable and effective universal influenza vaccine would have enormous ramifications for the control of influenza, a disease that claims an estimated 250,000 to 500,000 lives annually, including an average of 36,000 in the United States."

In parallel experiments with mice, ferrets and monkeys, Dr. Nabel and his colleagues first primed the animals' immune systems with a vaccine made from DNA encoding the influenza virus hemagglutinin (HA) surface protein. After being primed with DNA vaccine, the mice and ferrets received a booster dose of the 2006-2007 seasonal influenza vaccine or a vaccine made from a weakened cold virus (an adenovirus) containing HA flu protein. Monkeys were boosted with the seasonal flu vaccine only.

This prime-boost vaccine stimulated an immune response to the stem of the lollipop-shaped hemagglutinin of influenza virus. Unlike HA's head -- which mutates readily, allowing the virus to become unrecognizable to antibodies -- the stem varies relatively little from strain to strain. In principle, Dr. Nabel explains, antibodies generated against the stem of HA should be able to recognize and neutralize multiple flu strains.

Although the DNA in the priming vaccine was derived from a 1999 circulating flu virus, all the animals made antibodies capable of neutralizing virus strains from several other years. Mice and ferrets produced antibodies not only against virus strains dating from before 1999, including a strain that emerged in 1934, but also against strains that emerged in 2006 and 2007.

Moreover, although the prime-boost vaccines were both made from H1 subtypes of influenza A virus, the antibodies they generated neutralized other influenza subtypes, including H5N1 (avian influenza) virus. This indicates that a prime-boost strategy potentially could confer immunity to many or all subtypes of influenza A, says Dr. Nabel.

In another set of experiments, the scientists measured how well the prime-boost vaccine protected mice and ferrets from infection with deadly levels of flu virus. Three weeks after receiving the boost, 20 mice were exposed to high levels of 1934 flu virus, and 80 percent survived. Mice receiving DNA only, seasonal flu vaccine only or a sham prime-boost vaccine all died.

The researchers saw similar results when they tested several prime-boost combinations in ferrets, which are considered a good animal model for predicting flu vaccine efficacy in humans. All four ferrets that received a DNA prime-seasonal boost were protected from infection with a 2007 virus strain, while all six ferrets that received the DNA prime-cold virus boost combination were protected from the 1934 influenza virus.

Collaborators on these studies included Terrence Tumpey, Ph.D., of the Centers for Disease Control and Prevention.

"We are excited by these results," says Dr. Nabel. "The prime-boost approach opens a new door to vaccinations for influenza that would be similar to vaccination against such diseases as hepatitis, where we vaccinate early in life and then boost immunity through occasional, additional inoculations in adulthood."

Trials of prime-boost influenza vaccines assessing safety and ability of the vaccine to generate immune responses are already under way in humans, Dr. Nabel adds. The information from the new research will be valuable in selecting candidates to move forward into large-scale trials, he says. "We may be able to begin efficacy trials of a broadly protective flu vaccine in three to five years."



--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Scientists 'Clone' Human Virus Responsible for Congenital Malformations and Other Life-Threatening Diseases

A team of Welsh scientists has successfully cloned a human virus, offering new hope for the treatment of potentially life-threatening diseases.

Human cytomegalovirus (HCMV) is a major infectious cause of congenital malformations worldwide. The virus is also known to cause life-threatening disease in transplant patients and people with HIV/AIDS.

The development of new treatments has been hampered as scientists have been unable to stably replicate HCMV outside the human body.

Dr Richard Stanton from Cardiff University's School of Medicine who led the joint research, said: "HCMV has by far the largest genome of all viruses affecting humans -- consequently it was technically difficult to clone in an intact form in the laboratory.

"Cloning a copy of the virus from a strain isolated by Cardiff Public Health Laboratories has enabled us to identify the genes causing the instability of the virus outside the body.

"Following the identification of these genes, we have successfully developed cells in which we can grow virus that corresponds to that which exists in the human body."

Cloning the virus for the first time will help virologists develop antivirals and vaccines against the virus that causes clinical disease.

Following the study, the clone has already been distributed to research laboratories worldwide, and is being tested by the World Health Organisation (WHO) as part of a study to develop an international diagnostic standard with which to compare clinical isolates.

The genome sequence of the Cardiff virus has also been designated the international reference for HCMV in the National Centre for Biotechnology Information (NCBI) -- an international database that provides reference standards for biomedical and genomic information.

Dr Stanton added: "HCMV has been designated as a highest priority vaccine target by the US Institute of Medicine. When developing vaccines, anti-viral agents and improving understanding of disease, it is crucial to work with a virus that accurately represents the virus present in patients.

"For the first time our work has enabled us to create an exact copy of the virus outside of the body offering a vital step forward in the development of new treatments."

The study, published in the The Journal of Clinical Investigation and funded by the Wellcome Trust and the Medical Research Council, was a joint collaboration between Cardiff University's Infection, Immunity and Inflammation Interdisciplinary Research Group and Drs Davison and Dargan at the Centre for Virus Research at the University of Glasgow.

The virus, named Merlin, was isolated from a clinical sample identified by the Diagnostic Unit, Public Health Wales.

Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication -- is available in the on-line edition of The Journal of Clinical Investigation.



--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

New Plastic Blood Could Save Lives

Scientists create 'plastic' blood

The researchers said the artificial blood was easier to store Scientists have developed an artificial plastic blood which could act as a substitute in emergencies.
 Researchers at Sheffield University said their creation could be a huge advantage in war zones.

They say that the artificial blood is light to carry, does not need to be kept cool and can be kept for longer.

The new blood is made up of plastic molecules that have an iron atom at their core, like haemoglobin, that can carry oxygen through the body.

The scientists said the artificial blood could be cheap to produce and they were looking for extra funding to develop a final prototype that would be suitable for biological testing.

'Very excited'

Dr Lance Twyman, of the university's Department of Chemistry, said: "We are very excited about the potential for this product and about the fact that this could save lives.

"Many people die from superficial wounds when they are trapped in an accident or are injured on the battlefield and can't get blood before they get to hospital.

"This product can be stored a lot more easily than blood, meaning large quantities could be carried easily by ambulances and the armed forces."

A sample of the artificial blood prototype will be on display at the Science Museum in London from 22 May as part of an exhibition about the history of plastics.

 

How plastic blood could move from test tube to battlefield

We're all familiar with the calls for blood donors. But donated blood, while valuable, also poses risks to the recipient, including diseases such as hepatitis C or HHIV, the virus that causes Aids.

Wouldn't an artificial form be better? It could be made completely sterile, and might even be manufactured in dehydrated form: just add water and you have a litre of O negative, the universally transfusible version, which could be easily transported to locations where it was needed, or stored against future need.

Lance Twyman is trying to do just that: with a PhD from the University of Kent, he's working to make usable plastic blood in his University of Sheffield laboratory.

Twyman has long been interested in creating molecules that mimic nature, including synthetic enzymes to catalyse novel reactions. Early in his career he came across porphyrins, hollow square-shaped molecules which combine readily with metals like iron. "The iron is in the centre of the molecule, just like haemoglobin," says Twyman.

Things are not quite the same in nature, of course. Although the oxygen-carrying protein haemoglobin in your red blood cells contains an iron-based porphyrin to bind oxygen reversibly (so it can grab oxygen from the air in the lungs, and then give it up at the tissues), porphyrin alone won't work. "It clumps together or ends up reacting with the oxygen rather than just binding it," says Twyman. "But if you combine porphyrin chemistry and polymer chemistry, you can make a molecule which mimics haemoglobin."

Oxygen binding

Making an artificial blood might not have occurred to Twyman were it not for a chance discussion with a cardiologist. Although perfect blood substitutes are a clinician's dream, creating something just to carry oxygen around the bloodstream seemed intriguingly feasible.

Developed over the past five years, Twyman has now done just that by combining a porphyrin with monomers that build together in a hyper-branching or tree-like structure. His molecule is remarkably similar to haemoglobin in size and shape, while providing exactly the right environment around the porphyrin core for iron to bind and release oxygen. And the polyethylene glycol (PEG), a water-soluble polymer used to assemble the branched structure is already used for medical applications.

So what does it look like? Twyman's plastic blood is a dark red water-soluble paste with the consistency of honey. As with real blood, the colour comes from the porphyrin.

Putting plastic blood into your body - even to save your life - sounds risky. But Twyman points out that porphyrins are natural. He also reckons that the polymer component would be ignored by the body's immune system; there is some reassurance from existing medical uses. So far, though, his experimentation is confined to the test tube.

"At the moment, we have no idea regarding the polymer's lifetime in the body. However, for its intended application, a short lifetime is an advantage," says Twyman. "One obvious application is the battlefield or site of a major incident where replacing blood loss quickly can save lives."

Unlike donated blood, it's easy to store and is stable at room temperature. A second-generation molecule is now being developed for more rigorous investigation and, if all goes well, human use may eventually follow.

Professor Adrian Newland, president of the Royal College of Pathologists, says that people have worked on artificial blood for many years. It remains the medical equivalent of the holy grail - mainly because small foreign molecules in blood substitutes are swiftly removed from the bloodstream by the kidneys. "The drive has been to develop a larger molecule that will stay in the circulation and carry oxygen to the tissues," Newland says.

The EU-funded Euro Blood Substitutes consortium is also undertaking such research and includes biochemist Professor Chris Cooper of the University of Essex. He says that there are two types of blood substitutes - haemoglobin-based substitutes, which use human or bovine haemoglobin, and the perfluorocarbons. "Many compounds have gone into clinical trials and there are currently two products licensed for use," Cooper says.

Twyman's work now offers a third possibility that doesn't depend on haemoglobin supplies. "It's an interesting bit of chemistry. What they have to do is prove that the molecule is stable for hours in the presence of oxygen," Cooper says. "The phrase 'plastic blood' is cute, but a bit of a red herring as all blood substitutes add PEGs [polyethylene gycols]."

Body's defences

Newland worries about using PEGs in the body in transfusion quantities, although small-scale medical use is well established in association with drug delivery. "The amount of PEG that you'd give with artificial blood is several times larger than the amount we give attached to a simple drug. There needs to be some idea of what happens to PEG if it's given in that volume," Newland says.

While Twyman cannot yet answer such concerns, he says his approach uses a branched PEG, not the simple linear PEGs found with haemoglobin-based blood substitutes. "Hb [haemoglobin] work uses Hb extracted from animal or human blood. This has to be protected from the body's defences, usually using linear PEGs. These do work, but they migrate into the fatty lining of veins, which causes toxic effects. They also cause high blood pressure and there are ethical/religious issues regarding their general use," Twyman says.

Newland says that modified haemoglobin doesn't stay in the blood circulation long and can cause allergic-type reactions. But once haemoglobin is removed from the body's red blood cells, no cross-matching is needed before use.

An oxygen-carrying molecule that mimics haemoglobin would have universal donor characteristics - although the immune response and clearance time from the bloodstream is as yet unknown.

"If you are giving artificial blood, you don't have to worry about the transmission of infection from blood from donors, shelf life and the lack of availability from donations," Newland says. "It's a very interesting concept."

While Twyman believes his work might find military use one day, the Ministry of Defence is unwilling to comment until more research has been done. Meanwhile, the plastic blood will be in "Plasticity - 100 years of making plastics" at London's Science Museum from May 22. Plastic blood may yet benefit people beyond laboratories.



--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Scientists find short-sightedness gene

Scientists say they are one step closer to solving the most common eye disorder in the world - myopia or short-sightedness.

An international genetic research project studying more than 13,000 twins has uncovered a key gene that causes the disorder.

Professor David Mackey, an ophthalmologist at the Lions Eye Institute in Western Australia, was part of the project to identify the exact genes responsible for myopia.

The international study, which included researchers from the Queensland Institute of Medical Research, appears today in the journal Nature Genetics.

"We analyse usually around 600,000 DNA markers and find which markers tend to run more commonly with the feature that we are measuring - in this case myopia," says Mackey.

"And in collaboration with the twin research group in London we have been able to identify one new gene associated with myopia, mainly in older people."

Myopia epidemic

Mackey says three million Australians suffer from the condition, but there has been a myopia epidemic across Asia.

"Particularly Singapore, Taiwan, Hong Kong and now the large developing cities in China, [where] a majority of children when they finish high school are myopic, needing to wear glasses," he says.

"Now this is something that has happened really in the last 50 years and we are not sure what it is that led to this epidemic but we suspect that the east Asians are more genetically predisposed to getting myopia.

"Therefore understanding the underlying mechanism is of great importance, particularly if we are not having to supply glasses to the entire population of east Asia."

Intervention

Mackey says this gene is one of a dozen that need to be identified to help solve the bigger puzzle.

But he hopes the breakthrough will help develop new treatments and identify risk factors for the condition.

"One of these particular genes involved in the risk of myopia is something that we can actually develop a drug to intervene for, or we may be able to come up with other treatments, such as whether people should or shouldn't wear glasses all the time, whether they should get outdoors, or how much reading should they be doing," he says.

"All of these are factors that have been proposed as risk factors for developing myopia in those who are predisposed to get it."



--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Biochemistry checklist for csir

1. Three compulsory lists that must be at your tips-

  • · Ketogenic and Glucogenic amino acids.
  • · Essential and Nonessential amino acids.
  • · Basic, Acidic, Sulphur containing amino acids.

2. Regulatory Enzymes of pathways e.g.

  • · Citrate synthesis in citric acid cycle.
  • · Phosphofructokinase in Glycolysis.
  • · Pyruvate dehydrogenase in Pyruvate Oxidation.
  • · Pyruvate Carboxykinase in Gluconeogenesis.
  • · Glycogen Synthase in Glycogenesis.
  • · Phosphorylase in Glycogenolysis.
  • · G6PD in PPP.
  • · HMG CoA reductase in cholesterol synthesis.

3. Search for ATP estimates e.g.,

  • · 8 ATP's per Glucose molecule in Glycolysis under aerobic conditions.
  • · 30 ATP's per Pyruvate molecule entering citric acid cycle.
  • · 129 ATP's per palmitate undergoing boxidation.

4. Look for regulatory molecules and feedback inhibitions e.g.,

  • · Glucose-6-phosphate inhibition on hexokinase.
  • · Citrate's inhibitory effect on phosphofructokinase 1.
  • · Alanine's inhibitory effect on Pyruvate kinase.
  • · Acetyl CoA's inhibitory effect on Pyruvate dehydrogenase.
  • · Long chain acyl CoA's inhibitory effect on Acetyl CoA carboxylase.

5. Look for subcellular organelles where the reactions specifically occur.

  • · Enzymes of citric acid cycle in mitochondrial matrix.
  • · Enzymes of Glycolysis in cytosol.
  • · Enzymes of pentose phosphate pathway in cytosol.
  • · Enzymes of denovo synthesis of fatty acids in cytosol.
  • · Enzymes of fatty acid oxidation in mitochondria.

6. Always have a clarity regarding precise role of various lipoproteins.

  • · HDL is cholesterol scavenger.
  • · Chylomicrons carry dietary cholesterol.
  • · VLDL are vehicles of transport of triacylglycerol from the liver to extrahepatic tissues.

7. Vitamins and their role as coenzymes e.g.,

  • · Thiamine in oxidative decarboxylation.
  • · Niacin in dehydrogenase reactions.
  • · Pantothenic acid in CoA.
  • · Pyridoxal phosphate in muscle phosphorylase.
  • · Biotin in carboxylase enzymes.
  • · Vitamin B12 to produce succinyl CoA.
  • · Folate in transfer of one-carbon units.

8. Products that accumulate in metabolic disorders e.g.,

  • · Homogenisate in urine of Alkaptonuria patients
  • · Phenyl acetyl glutamine in phenylketonuria.
  • · Xanthurenate in Vitamin B6 deficiency.
  • · Branched chain ketonuria in Mapple syrup urine disease.

9. Check for key enzymes responsible for Metabolic disorders e.g.,

  • · Glucose-6-phosphates in von Gierkes.
  • · Hepatic fructokinase in essential fructosuria.
  • · Galactose-1-phosphate uridyl transferase in Galactosemia.
  • · Cystathionine-b-synthase in homocystinuria.

10. Where NADH forms, where NADPH forms, where FADH2 forms, where substrate level phosphorylation occurs e.g.,

Are your laboratory autoclaves actually working properly?

HERE IS AN INTERESTING STEP TO AUDIT YOUR AUTOCLAVE'S FUNCTIONING..SPECIALLY FOR STUDENTS..
U ALL KNOW that autoclave is a device which is used for sterlization(heat) at laboratory as well as industrial levels.This mode of Sterlization involves a heating ,a cooling, and a HOLDING period.The temprature and pressure during holding is 121 degrees centigrade and 121 psi .
BUT, are u sure that the sterlization u perform at your laboratories is good enough??..
Here is a checking trick for it. i came to know about it during my training at CENRAL RESEARCH INSTITUTE ,KASAULI.
We can use INDICATOR TAPES while autoclaving process.chemical indicator tapes have certain chemicals which undergo a specific colour change only if right temprature and pressure conditions are attained for the required holding period( 15 minutes)..
This information may not be that good but it was something new which triggered an engineering feel within me, and to the extent i should analyze things going around.

--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Wisdom teeth useful after all, have stem cells

NEW DELHI: The good for nothing painful wisdom tooth may finally have some worth.

Doctors say the wisdom tooth, which is usually extracted, is a rich source of stem cells. The soft pulp inside the tooth contains a population of cells — known as mesenchymal stromal cells — which are similar to cells found in bone marrow, a common stem cell source.

However, unlike bone marrow, tooth pulp is more easily obtained, especially in wisdom teeth that most individuals get removed anyway, said Dr Franck Chaubron from the Institute Clinident Biopharma. Dr Chaubron, who was recently in the country to set up Stemade Biotech, India's first dental stem cell bank that will be launched in a month in Chennai, said international studies conducted with stem cells extracted from a wisdom tooth have shown tremendous promise in regenerating damaged bones, cornea and cardiac muscles.

"You don't necessarily have to remove the wisdom tooth to extract the stem cells from the pulp. Usually, the pulp has a million cells, 20% of which will be stem cells. It can be extracted from a person aged between 12 and 30. Dental stem cells are very easy to extract. They have high quantity of stem cells in them and can be applied for many regenerative applications," Dr Chaubron told TOI.

On Saturday, in a new study in the "Journal of Biological Chemistry" scientists from Japan's National Institute of Advanced Industrial Science and Technology confirmed that third molars — commonly known as wisdom teeth — are a valuable reservoir of stem cells.

"Thus everyone might be carrying around his or her own personal stem-cell repository should he or she ever need some," the scientists said.

The researchers, led by Hajime Ohgushi, collected tooth samples from three donors and managed to generate a series of stem cell lines which displayed varying degrees of "robustness but in some cases proliferated quite well, up to 100 times more efficiently than typical skin-cell-derived stem cells. The molar-derived cells also could differentiate into many other cell types including beating cardiomyocytes."

Shailesh Gadre, MD of Stemade, said, "We have also harvested excellent amounts of stem cells from children's milk tooth. Wisdom tooth extraction is a common medical procedure in developed nations. If done in a sterilised setting, we can freeze the cells in liquid nitrogen for years until needed by which time its new applications will be found by researchers working on dental stem cells."

Scientists say the dental stem cells are located in areas next to nerve and blood vessels within the pulp of the tooth. Stem cells are master cells of the body that are not yet specialised and differentiated for a particular function/organ or tissue application. These stem cells have been found in tissues such as brain, bone marrow, blood, blood vessels, skeletal muscles, skin and liver.

They remain in a quiescent or non-dividing state for years until activated by disease or tissue injury.

--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Now one blood group fits everyone

A new discovery was made by international scientific team who established a way to convert one blood group into another.

The finding can revolutionize medicine as it means there will be no lack of blood supplies. The study conducted by experts from University of Copenhagen published their results in Nature Biotechnology journal, where it is stated that O blood group can be a source for all the other blood types (A, B and AB).

If earlier the mistake of giving wrong blood group could lead to hazardous reactions from the immune system and in severe cases result in death, now all blood groups can be converted into one O group and used furthermore.

It is known that blood group of those who have A and B groups has sugar molecules that respond differently to other blood group. People AB blood group is the rarest one and their blood contains both antigens. Transfusion of the different than individual's blood group is a serious impact on the immune system and incompatibility may become crucial.

Studying more than 2,500 bacteria and fungi experts found proteins that can act as destroyers of sugar molecules. Scientists discovered bacterial enzymes from Elizabethkingia meningosepticum and Bacterioides fragilis that are able to remove sugar molecules from the blood cells thus making one blood match other blood groups.

After test trials new blood where A, B and AB blood groups will be converted into O group is anticipated to be used in hospitals.

The National Blood Service now has 40,000 of blood samples that can be enough for about five days.

--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Saturday, September 18, 2010

RFRI Jorhat Botany/Zoology JRF Vacancies
Title of the project with PI name: Assessment of insect pest problems of selected bamboo species in Assam and their management
PI: Sh. R. Raja Rishi
Junior Research Fellow (01)
Essential Qualification M.Sc. in Agriculture Entomology/M.Sc. Zoology with Entomology specialization/M.Sc. life Science.
Desirable qualification: Entomology background and knowledge in computer application
Emoluments: Rs. 12,000 + HRA as per rule
As Above Initially for one year which may be extended
The Posts are purely temporary. The Selected candidate may not claim for regular appointment at this Institute. The JRF, Field Assistants and Technical Assistants will have to assist the P.I. in doing the different field works. The walk-in-interview will be held on 8th July, 2010 (11.00 AM) in the Conference Hall, Rain Forest Research Institute, Jorhat, Assam.
The Candidates are requested to report the reception between 9.30 AM to 10.30 AM and submit their applications on the prescribed format. Original Certificates must be produced at the time of Interview. Candidate may apply more than one post. The decision of the Director, RFRI, Jorhat will be final and binding in all the matter pertaining to screening, interview and final selection.

No TA/DA will be admissible for appearing in the interview.
Adress:
Rain Forest Research Institute
P. Box No. 136
Jorhat, Assam
Source: http://www.icfre.org/UserFiles/File/advertisement_job/RFRI-Recruitment-JRF-&-FA-280610.pdf

--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

Saturday, September 11, 2010

Saturday, September 4, 2010

csir questions

CSIR Questions !

Todays set of Questions are:
1) ras mutations are inherited to next generation through?
(a) environmental factors
(b) germ line mutations
(c) somatic mutation
(d) spontanous mutation
(e) none

2) Aberrent activation of------- pathway can contribute to the oncogenicity?
(a) anaerobic
(b) mitogenic
(c) carboxylic
(d) aerobic
(e) all

3) Which tumor suppressor gene is most frequently mutated in human cancers?
(a) RB12
(b) TP53
(c) RB84
(d) TP13
(e) ALL

4) Name one prominent factor in the response that arrests the cell
cycle which is activated by P53?
(a) TP53
(b) p21
(c) P-RB
(d) P-APC
(e) RB21

5) p21 is synthesized due to the cell stress by inactivating---------?
(a) DNA repair
(b) cyclins/CDKs complex
(c) protein complex
(d) DNA transcription
(e) all

6) START usually occurs during?
(a) mid-S
(b) mid-G1
(c) end of S
(d) mid-G2
(e) end-G1

7) The most common form of a dominant negative mutant is one that
forms -------- protein containing both mutant and wild type subunits
in p53?
(a) monomeric
(b) homomeric
(c) heteromeric
(d) polymeric
(e) none

8) Tumor T antigens have a variety of function in --------- type of cycle
(a) translation
(b) lytic
(c) lysogenic
(d) translocation
(e) reciprocation

9) The important of the connection between tumorigenesis and loss of
apoptosis is also shown by the properties of the ----- oncogenes?
(a) RB
(b) bcl2
(c) bcl8
(d) p53
(e) all


--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343

An HIV vaccine is the theoretical vaccine which would be given to
persons without HIV in order to vaccinate them against getting HIV,
the virus which causes AIDS. No effective vaccine against HIV exists.
As there is no known cure for AIDS, the search for a vaccine has
become part of medical approaches against the disease.
It has been known for many years that HIV is an extremely difficult
virus to render harmless, and no cure presently exists. Research into
a vaccine is one of several strategies to reduce the worldwide harm
from AIDS, with other approaches based upon antiviral treatments such
as highly active antiretroviral therapy (HAART), and social approaches
such as safe sex.
There is evidence that a vaccine may be possible. Work with monoclonal
antibodies (MAb) has proven that the human body can defend itself
against HIV, and certain individuals remain asymptomatic for decades
after HIV infection. More recently in 2009, a number of potential
candidates for antibodies and early stage results from clinical trials
have been announced by various teams. However these are early results,
and have either not been developed to the point of human testing, or
not fully peer reviewed and replicated by other teams, at this time.

--
support4bt@gmail.com
www.sitbiotech.blogspot.com
www.sitbiotech.yolasite.com
9739461028
9037652343